| __timestamp | Novavax, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19928000 | 1499100000 |
| Thursday, January 1, 2015 | 30842000 | 1923500000 |
| Friday, January 1, 2016 | 46527000 | 2351400000 |
| Sunday, January 1, 2017 | 34451000 | 2564000000 |
| Monday, January 1, 2018 | 34409000 | 2397300000 |
| Tuesday, January 1, 2019 | 34417000 | 2503400000 |
| Wednesday, January 1, 2020 | 145290000 | 3344600000 |
| Friday, January 1, 2021 | 298358000 | 4529200000 |
| Saturday, January 1, 2022 | 488691000 | 4179100000 |
| Sunday, January 1, 2023 | 468946000 | 4650100000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Novavax, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently outpaced Novavax, Inc. in SG&A spending, with expenses peaking at approximately $4.65 billion in 2023, a staggering 900% higher than Novavax's $469 million. This trend highlights Viatris's aggressive market strategies and operational scale. Meanwhile, Novavax's expenses surged by over 2,200% from 2014 to 2023, reflecting its rapid growth and increased market presence. These insights underscore the contrasting financial strategies of these pharmaceutical giants, offering a window into their operational priorities and market positioning.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Novavax, Inc.
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: MorphoSys AG vs Novavax, Inc.
Mesoblast Limited vs Novavax, Inc.: SG&A Expense Trends
Wave Life Sciences Ltd. and Novavax, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Dynavax Technologies Corporation and Novavax, Inc.